Open AccessConsolidation Treatment and Long-Term Prognosis of Rituximab in Minimal Change Disease and Focal Segmental Glomerular Sclerosis
Author(s) -
Lin Li,
Weiming Wang,
YiFan Wu,
Jingyuan Xie,
Li Xiao,
Xiaoxia Pan,
Wen Zhang,
Jing Xu,
Yikai Cai,
Hong Ren,
Nan Chen
Publication year - 2021
Publication title -
drug design, development and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.964
H-Index - 64
ISSN - 1177-8881
DOI - 10.2147/dddt.s302257
Subject(s) - medicine , minimal change disease , rituximab , consolidation (business) , retrospective cohort study , odds ratio , proportional hazards model , surgery , focal segmental glomerulosclerosis , glomerulonephritis , kidney , lymphoma , accounting , business
There is currently a lack of studies investigating long-term prognosis and the necessity of further rituximab (RTX) consolidation treatment for minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS). The aim of this study was to evaluate the efficacy of RTX for these diseases and to investigate whether a consolidation treatment can lower risks of relapse and reinforce long-term remission.